- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07775235
Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Assessment of Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Descrizione dettagliata
The primary feature of idiopathic inflammatory myopathies (IIM) is inflammation of muscles, yet extra-muscular manifestations are common such as interstitial lung disease (ILD). Based on both muscular and extra-muscular features, patients can fall into different types of IIMs, including broad subtypes of dermatomyositis (DM), polymyositis (PM), inclusion-body myositis (IBM) and immune-mediating necrotizing myopathies (IMNM). Particular subtypes such as dermatomyositis patients positive for anti-melanoma differentiation-associated protein 5 (anti-MDA5) are most commonly associated with rapidly progressive lung involvement and high mortality, with survival at 1 year being less than 60% despite current available treatment. Treatment for IIM patients involves immunosuppression, though there is no consensus or treatment guidelines available for different subtypes, particularly for myositis-associated RP-ILD. Despite several trials having shown increased efficacy with more aggressive immunosuppressive regimes, mortality still remains high. There is thus an unmet need with regards to treatment of patients with IIM, particularly for myositis-associated RP-ILD.
There is an urgent need to improve outcomes in myositis-associated RP-ILD. Till date, there are no randomised controlled trials that investigate therapy of myositis-associated RP-ILD likely due to the low incidence of the disease. Current best level of evidence for therapies come from single-arm prospective cohort studies with comparison with historical controls. Recent studies using combination therapy to target different aspects of these pathological processes have demonstrated increased efficacy compared to single target alone. This shows that appropriate selection of targets with subsequent combination blockade will be beneficial in treatment of patients with myositis associated RP-ILD. Hence, the investigators propose the utilization of rituximab to block the B-cell involvement, tacrolimus to target T-cells, tofacitinib to block interferon signaling with steroids due to their effects on both the innate and adaptive system in the treatment of myositis-associated RP-ILD. Such combination therapy allows precise targeting of pathways responsible for pathophysiology of the disease, without high individual dosages and hence reducing potential side effects. Till date there are no prospective studies that look into current combination of steroids, tacrolimus, tofacitinib and rituximab in the patients with myositis-associated RP-ILD. However, a drawback for increased immunosuppression is infection, particularly with cytomegalovirus (CMV). The investigators will employ a prophylactic treatment strategy to mitigate the risk of increased infection following higher intensity immunosuppression.
The primary end point will be survival rate at 6 months from initiation of treatment.
Secondary end points include improvement of clinical status, biochemical markers, radiological appearance and parameters on lung function test. Secondary end points also include adverse events rate including side effects from treatment and infection rates.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Mohamad Fadhli Bin Masri, MD PhD
- Numero di telefono: 6576 2609
- Email: mohamad.fadhli@mohh.com.sg
Luoghi di studio
-
-
-
Singapore, Singapore
- Reclutamento
- Singapore General Hospital
-
Contatto:
- Mohamad Fadhli Bin Masri, MD PhD
- Numero di telefono: 6576 2609
- Email: mohamad.fadhli@mohh.com.sg
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Adulto
- Adulto più anziano
Accetta volontari sani
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- Age of 21 years or above;
- Diagnosis of myositis associated rapidly progressive interstitial lung disease
Exclusion Criteria:
- Age of less than 21 year old;
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
|---|---|
|
Treatment group
Patients with immune-mediated myositis-associated rapidly progressive interstitial lung disease undergoing treatment with combined immunosuppressive treatment
|
Combination treatment regimen lasting 6 months with A) Steroids: Starting with Intravenous methylprednisolone (500mg once daily for three days) followed by tapering dose of prednisolone B) Rituximab (1000mg given at the start of treatment and 1000mg 2 weeks after the first dose) C) Tacrolimus D) Tofacitinib
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
All-cause mortality at 6 months from treatment initiation
Lasso di tempo: 6 months
|
Proportion of total participants who demise from all cause till 6 months from treatment initiation (percentage of all participants)
|
6 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in clinical status through Modified Medical Research Council Dyspnea Scale
Lasso di tempo: 6 months
|
The Modified Medical Research Council (mMRC) Dyspnea Scale will be used to rate participants' functional status at start of treatment and at 6 months post treatment (0 to 4).
|
6 months
|
|
Change in clinical status through requirement of supplemental oxygen at 6 months
Lasso di tempo: 6 months
|
Proportion of participants who require oxygen supplementation at the start of treatment and 6 months post treatment (percentage of all participants).
|
6 months
|
|
Safety of treatment regimen in participants
Lasso di tempo: 6 months
|
Number of adverse infection events experienced by participants
|
6 months
|
|
Safety of treatment regimen in participants
Lasso di tempo: 6 months
|
Number of adverse haematological events leading to change of medication as per managing physician
|
6 months
|
|
Safety of treatment regimen in participants
Lasso di tempo: 6 months
|
Number of adverse biochemical events leading to change of medication as per managing physician
|
6 months
|
|
Change in biochemical markers of disease activity
Lasso di tempo: 1 year
|
Levels of C-reactive protein (mg/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year
|
1 year
|
|
Change in biochemical markers of disease activity
Lasso di tempo: 1 year
|
Levels of Erythrocyte sedimentation rate (mm/h) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Lasso di tempo: 1 year
|
Levels of Ferritin (ug/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Lasso di tempo: 1 year
|
Levels of Lactate dehydrogenase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Lasso di tempo: 1 year
|
Levels of Creatine kinase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
|
Change in biochemical markers of disease activity
Lasso di tempo: 1 year
|
Levels of Aldolase (U/L) during treatment will be measured at start of treatment, 1 month, 3 month, 6 month and 1 year.
|
1 year
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie muscoloscheletriche
- Malattie del sistema nervoso
- Malattie muscolari
- Malattie neuromuscolari
- Malattie delle vie respiratorie
- Malattie polmonari
- Malattie polmonari, interstiziale
- Miosite
- Aminoacidi, peptidi e proteine
- Proteine
- Prodotti chimici organici
- Composti policiclici
- Anticorpi, monoclonali
- Anticorpi
- Immunoglobuline
- Immunoproteine
- Proteine del sangue
- Globuline sieriche
- Globuline
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Macrolidi
- Lattoni
- Incintadienetrioli
- Anticorpi, monoclonali, derivati da murina
- Rituximab
- Prednisolone
- Tacrolimo
- tofacitinib
Altri numeri di identificazione dello studio
- 2024/2307
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .